This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rinaldi, M. Articles by Fazio, V. M. Search for Related Content PubMed PubMed Citation Articles by Rinaldi, M. Articles by Fazio, V. M.

Antibodies Elicited by Naked DNA Vaccination against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients’ Tumor Cells¹

Laboratory for Molecular Medicine and Biotechnology, Università Campus Bio-Medico, 00155 Rome [M. R., P. P., V. M. F.]; Institute of General Pathology, Università Cattolica S. C., 00168 Rome [F. R.]; Institute of Experimental Medicine, CNR, 00133 Rome [M. R., E. S., I. V., V. M. F.]; Departments of Experimental Medicine and Biochemical Sciences [S. A. C., M. G. F.] and Surgery [M. L.], University of Rome "Tor Vergata," 00133 Rome; Department of Clinical and Biological Sciences, S. Luigi Hospital, Università di Torino, 10043 Turin [A. S., G. S.]; and Laboratory of Molecular Pathology and Gene Therapy, IRCCS H. "Casa Sollievo della Sofferenza," 71013 San Giovanni Rotondo (FG) [E. S., V. M. F.], Italy

Several reports have suggested that the mechanism of protection induced by antiidiotypic vaccination against low-grade lymphoproliferative disorders is likely to be antibody mediated. Here we test the hypothesis that DNA vaccination with the short peptide encompassing the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain (VH-CDR3) may elicit a specific antibody immune response able to recognize the native antigens in the form required for therapy. As a test system, we used the VH-CDR3 sequences derived from two patients with non-Hodgkin’s B lymphomas (PA, AS) and one patient with hairy cell leukemia (BA) to immunize outbred Swiss mice. This experimental model could mimic a clinical setting in which different patients present distinct HLA haplotypes. Individual tumor-specific VH-CDR3 sequences were amplified by a two-step procedure and directly cloned into multigenic plasmid vectors (pRC100 and derived) with and without mouse interleukin 2 (mIL-2). Each tumor-specific sequence was characterized by sequencing. Female Swiss mice were vaccinated i.m. with plasmids expressing the tumor-specific VH-CDR3 sequence alone (pRC101-PA), mIL-2 plus the VH-CDR3 sequence (pRC111-PA), or a different unrelated antigen (NS3 of hepatitis C virus; pRC112), the sole mIL-2 (pRC110), and the empty plasmid (pRC100). Boost injections were performed at 3 and 16 weeks from the first vaccination, and sera were drawn before each vaccination and at 6, 9, and 19 weeks. Induction of anti-VH-CDR3s antibodies in the sera and their ability to recognize native antigens on patients’ tumor cells were evaluated by FACS analysis. Up to 56% (n = 25) of mice vaccinated with pRC111-PA plasmid and 20% (n = 15) of mice vaccinated with pRC101-PA developed a specific immune response that was maintained throughout 19 weeks of observation in 40% of pRC111-PA-vaccinated mice. No response was detected in sera obtained from mice vaccinated with the other plasmids (n = 45). pRC111-PA injection s.c. was less effective (13%, n = 15) than i.m. injection (53%, n = 15).

Indeed, we demonstrated that antibodies elicited by naked DNA vaccination against three different patient-derived VH-CDR3 peptides (pRC111-PA or BA or AS) readily reacted with binding epitopes on the idiotypic proteins expressed on the surface of tumor cells derived from each patient; 60, 40, and 40% of, respectively, PA-, BA-, and AS-vaccinated mice developed specific antibodies. No cross-reactivity was detected among the three different CDR3s against tumor cells derived from the other two patients.

The outbred mouse strategy confirmed the significant matching potential of three different VH-CDR3 peptides to be efficaciously presented through different MHCs. We conclude that individual VH-CDR3 DNA vaccination can result in a potentially effective specific immune response against non-Hodgkin’s B lymphoma cells by a rapid and low-cost therapeutic approach.

This article has been cited by other articles:

				B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF]

				M. Robin, J. Andreu-Gallien, M.-H. Schlageter, D. Bengoufa, I. Guillemot, K. Pokorna, C. Robert, J. Larghero, P. Rousselot, E. Raffoux, et al. Frequent antibody production against RAR{alpha} in both APL mice and patients Blood, September 15, 2006; 108(6): 1972 - 1974. [Abstract] [Full Text] [PDF]

				Y.-q. Wei, M.-j. Huang, L. Yang, X. Zhao, L. Tian, Y. Lu, J.-m. Shu, C.-j. Lu, T. Niu, B. Kang, et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen PNAS, September 5, 2001; (2001) 191112198. [Abstract] [Full Text] [PDF]

				Y.-q. Wei, M.-j. Huang, L. Yang, X. Zhao, L. Tian, Y. Lu, J.-m. Shu, C.-j. Lu, T. Niu, B. Kang, et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen PNAS, September 25, 2001; 98(20): 11545 - 11550. [Abstract] [Full Text] [PDF]